Subject: Georgia HCV Program -Epclusa
From: Ben Dunne <[email-masked]>
To: Tamar Gabunia <[email-masked]>, David Novoa <[email-masked]>, Sean Barr <[email-masked]>, Sopo Belkania <[email-masked]>
Cc: Graeme Robertson <[email-masked]>, "[email-masked]" <[email-masked]>, Michael Clancy <[email-masked]>, Ekaterine Adamia <[email-masked]>, GAP <[email-masked]>, AOEM_SCM <[email-masked]>
Date: Fri, 28 Jun 2019 13:43:28 +0000

Hi Tamar,

Please find shipping documents attached and flight details below (note – total units 10,976)

Flight      From                     To

TK7796/28   DUBLIN                   LONDON

TK1986/30   LONDON                   ISTANBUL

TK386/1     ISTANBUL                 TBILISI, GEORGIA

From:                      DUBLIN

To:                        TBILISI, GEORGIA

Carrier:                   TK   = TURKISH AIRLINES INC.

Departure:                 28 June 2019, 20:00  Hrs from DUBLIN

Estimated Time of Arrival:  2 July 2019, 03:05  Hrs at TBILISI, GEORGIA

Kindest Regards

Ben

From: Tamar Gabunia [mailto:[email-masked]]

Sent: 25 June 2019 10:20

To: Ben Dunne; David Novoa; Sean Barr; Sopo Belkania

Cc: Graeme Robertson; [email-masked]; Michael Clancy; Ekaterine Adamia

Subject: [EXTERNAL] RE: Georgia HCV Program -Epclusa

Dear Ben

Many thanks for your prompt reply. Much appreciated!

პატივისცემით,

თამარ გაბუნია

მინისტრის მოადგილე

Sincerely,

Tamar Gabunia,
MD, MPH

Deputy Minister

From: Ben Dunne [mailto:[email-masked]]

Sent: 25 June, 2019 13:18

To: Tamar Gabunia <[email-masked]>; David Novoa <[email-masked]>; Sean Barr <[email-masked]>; Sopo Belkania <[email-masked]>

Cc: Graeme Robertson <[email-masked]>; [email-masked]; Michael Clancy <[email-masked]>; Ekaterine Adamia <[email-masked]>

Subject: RE: Georgia HCV Program -Epclusa

Hello Tamar,

We are planning to dispatch on Friday (we are expecting the balance of stock from our manufacturing site tomorrow), i have requested flight details and will
forward them to you later today.

Best Regards

Ben

From: Tamar Gabunia [mailto:[email-masked]]

Sent: 25 June 2019 06:48

To: David Novoa; Sean Barr; Sopo Belkania

Cc: Graeme Robertson; [email-masked]; Michael Clancy; Ben Dunne; Ekaterine Adamia

Subject: [EXTERNAL] Georgia HCV Program -Epclusa

Importance: High

Dear David

I am writing back regarding the Epclusa order status. May I kindly ask what’s an estimated delivery date to Georgia? Our current stock of the drug
is really low and we need to plan carefully before drugs arrive.

Many thanks for your understanding and cooperation.

პატივისცემით,

თამარ გაბუნია

მინისტრის მოადგილე

Sincerely,

Tamar Gabunia,
MD, MPH

Deputy Minister

From: David Novoa [mailto:[email-masked]]

Sent: 8 June, 2019 04:57

To: Tamar Gabunia <[email-masked]>; Sean Barr <[email-masked]>; Sopo Belkania <[email-masked]>

Cc: Graeme Robertson <[email-masked]>; David Sergeenko <[email-masked]>;
[email-masked]; Michael Clancy <[email-masked]>; Ben Dunne <[email-masked]>; Ekaterine Adamia <[email-masked]>

Subject: RE: Georgia HCV Program - Harvoni

Dear Tamar,

This is excellent news.

We will check the status of Epclusa and get back to you.

Have a great weekend,

David

From: Tamar Gabunia [mailto:[email-masked]]

Sent: Friday, June 07, 2019 8:55 AM

To: David Novoa; Sean Barr; Sopo Belkania

Cc: Graeme Robertson; David Sergeenko;
[email-masked]; Michael Clancy; Ben Dunne; Ekaterine Adamia

Subject: [EXTERNAL] RE: Georgia HCV Program - Harvoni

Dear David,

Thanks for your reply. We expect to utilize the existing Harvoni stock before its expiry date, based on the assumption that the current enrollment
rate is maintained/increased. Will provide the order as advised and can received the order as it becomes available.

I would like to take this opportunity and check with you the Epclusa order status. We are hoping to receive it by the end of June.

Many thanks for all your assistance.

პატივისცემით,

თამარ გაბუნია

მინისტრის მოადგილე

Sincerely,

Tamar Gabunia,
MD, MPH

Deputy Minister

From: David Novoa [mailto:[email-masked]]

Sent: 7 June, 2019 04:08

To: Tamar Gabunia <[email-masked]>; Sean Barr <[email-masked]>; Sopo Belkania <[email-masked]>

Cc: Graeme Robertson <[email-masked]>; David Sergeenko <[email-masked]>;
[email-masked]; Michael Clancy <[email-masked]>; Ben Dunne <[email-masked]>; Ekaterine Adamia <[email-masked]>

Subject: RE: Georgia HCV Program - Harvoni

Dear Tamar,

Thank you very much for the detailed update.

If I understand correctly, you might be able to fully use the existing Harvoni stock before its expiry date?

Please place the Harvoni order for the additional 7220 bottles, we will trigger the appropriate activities once received.

In case the product becomes available earlier, would you like to receive it before September?

Best regards,

David

From: Tamar Gabunia [mailto:[email-masked]]

Sent: Thursday, June 06, 2019 10:11 AM

To: Sean Barr; Sopo Belkania

Cc: Graeme Robertson; David Sergeenko;
[email-masked]; David Novoa; Michael Clancy; Alina Visnakova; Ben Dunne; Ekaterine Adamia

Subject: [EXTERNAL] Georgia HCV Program - Harvoni

Dear Sean

I hope all is well with you. With this I would like to provide you with updated information on HCV Program implementation and share our estimates
on the needed amount of Harvoni.

In general, from the beginning of the HCV program implementation more then 55 000 HCV patients were registered, more then 54 000 out of registered
patients have already started treatment and more than 51 000 completed treatment.

As you have already been informed, at this stage, we have patients on both treatment regimens, with Epclusa and with Harvoni; monthly registration
in the program is stable, with about 1000 -1100 patient (about 54% of patients are on treatment with epclusa regimens and 46% on harvoni regimens). The number of patients enrolled on Harvoni treatment is around 470-500 monthly. We think we will maintain the
current enrolment on Harvoni in the coming months.

With this picture of inflow, from June, until the end of the year, about 3500 new patients will be included in HCV program with Harvoni regimens.
The needed amount of Harvoni for current and new patients is around  11150 bottles. It should be noted that the current stock of Harvoni is 6930 bottles with the expiry date on December 31st. The total need of Harvoni (including the three months buffer stock
(additional 3000 bottles)) by the end of 2019 amounts to 7220 bottles.

Please kindly let us know if you have any questions or concerns on these estimates. If acceptable, we will provide an
official order for 7220 Harvoni bottles in the next few days.

Many thanks and look forward to hearing from you.

With Kind Regards,

პატივისცემით,

თამარ გაბუნია

მინისტრის მოადგილე

Sincerely,

Tamar Gabunia,
MD, MPH

Deputy Minister

From: Sean Barr [mailto:[email-masked]]

Sent: 18 April, 2019 22:45

To: Tamar Gabunia <[email-masked]>; Sopo Belkania <[email-masked]>

Cc: Graeme Robertson <[email-masked]>; David Sergeenko <[email-masked]>;
[email-masked]; David Novoa <[email-masked]>; Michael Clancy <[email-masked]>; Alina Visnakova <[email-masked]>;
Ben Dunne <[email-masked]>

Subject: RE: Georgia HCV Program - Current Stock and Future Supply

Dear Tamar,

Greetings to you as well and many thanks for this comprehensive update.  I’m glad to see the Epclusa rollout is progressing as planned.  Yes, please
go ahead and place an order for 11,000 Epclusa bottles.

Regarding Harvoni, I suggest we tentatively plan a packaging run of 3,000 to 5,000 bottles for delivery in September, to give you enough time to
replace the expiring product in November.  Let’s try to make sure you have enough to cover Q1 ’20 demand as well.  For all bottles expiring, we’ll need proof of destruction when the time comes.

Regards,

Sean

From: Tamar Gabunia [mailto:[email-masked]]

Sent: Wednesday, April 17, 2019 8:53 AM

To: Sean Barr; Sopo Belkania

Cc: Graeme Robertson; David Sergeenko;
[email-masked]; David Novoa; Michael Clancy; Alina Visnakova; Ben Dunne

Subject: [EXTERNAL] Georgia HCV Program - Current Stock and Future Supply

Dear Sean

Greetings! With this I would like to provide you with updated information on HCV Program and adjusted plan on treatment.

From the beginning of the HCV program implementation more then
55 000 HCV patients were registered, more then
54
000 out of registered patients
have already started treatment and more
than
50
000 completed treatment.

As you have already been informed,
at this moment, we have patients on both treatment regimens, with Epclusa and with Harvoni;

·
From December 2018, we included Epclusa in treatment regimens for all untreated (treatment naïve) or already treated (treatment experienced) patients with genotype 2 and 3, also, for already treated (treatment experienced) patients
with genotype 1 and 4. For all other patients we used Harvoni regimens.

·
Currently, the number of patients receiving Epclusa treatment regimens is about 550 per month and with Harvoni treatment regimens - about 500 per month.

·
With this picture of inflow, from now, until the end of the year, about 4950 new patients will be enrolled in HCV program on Epclusa containing regimens, out of them about 88% will be on 12-week regimens and 12% on 24-week treatment
regimens. To provide medicines for this group of patients, we will need about 17 400-bottles of Epclusa, by the end of the year. It should be noted that at the moment the number of Epclusa bottles remaining in central warehouse is about 6400, so the total
number of required bottles is 11 000 bottles (=17400-6400).

If our request is acceptable, we will provide an official order for 11000 Epclusa bottles in the next few days.

As for Harvoni, at the moment number of bottles, remaining at the warehouse is enough for about 6 months (the estimated number of
patients 500 per month on average). We estimate that 14000 bottles of Harvoni will be needed in April-December. Currently the available stock includes 10550 bottles with the expiry date on
December 31, 2019. We would appreciate your guidance on managing the available stock  given the anticipated expiry by the end of 2019.

Many thanks and look forward to hearing from you.

With Kind Regards,

Tamar Gabunia

Deputy Minister

From: Sean Barr [mailto:[email-masked]]

Sent: 24 March, 2019 19:10

To: Tamar Gabunia <[email-masked]>; Sopo Belkania <[email-masked]>

Cc: Graeme Robertson <[email-masked]>; David Sergeenko <[email-masked]>;
[email-masked]; David Novoa <[email-masked]>; Michael Clancy <[email-masked]>; Alina Visnakova <[email-masked]>;
Ben Dunne <[email-masked]>

Subject: RE: Georgia HCV Program - Current Stock and Future Supply

Dear Tamar,

Thank you and nice to meet you.  I look forward to the update.

Regards,

Sean

DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments
contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication
or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on
Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain
viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this
e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a
limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England

DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information
which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the
information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on
Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain
viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this
e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a
limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England